Avalo Therapeutics (AVTX) Total Liabilities (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Total Liabilities data on file, last reported at $31.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 98.42% year-over-year to $31.6 million; the trailing twelve-month figure through Mar 2026 stood at $31.6 million (up 98.42% YoY), and the FY2025 full-year result was $33.4 million, up 88.75% from the prior year.
• Total Liabilities for Q1 2026 stood at $31.6 million, down from $33.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $224.8 million in Q1 2024 and bottomed at $13.7 million in Q4 2023.
• The 5-year median for Total Liabilities is $33.6 million (2025), against an average of $49.6 million.
• The widest annual swing landed in 2024, when Total Liabilities surged 428.95%; it then plunged 92.92% in 2025.
• A 5-year view of Total Liabilities shows it stood at $44.3 million in 2022, then plunged by 69.09% to $13.7 million in 2023, then increased by 29.3% to $17.7 million in 2024, then jumped by 88.75% to $33.4 million in 2025, then slipped by 5.52% to $31.6 million in 2026.
• The last three Total Liabilities figures came in at $31.6 million (Q1 2026), $33.4 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.

Peer Comparison